Thrilled to share our collaborative study with Illumina, published in the Journal of Clinical Oncology (JCO) Precision Oncology! Using data from the Syapse Learning Health Network, we demonstrated that Comprehensive Genomic Profiling (CGP) significantly improves clinical outcomes for advanced NSCLC patients. This manuscript highlights the transformative potential of CGP in community oncology practices. Congratulations to the incredible teams at Illumina and Syapse for this impactful work!
I’m pleased to share some exciting insights published in the Journal of Clinical Oncology (JCO) Precision Oncology. Illumina’s Health Economics & Outcomes Research team, in collaboration with Syapse, leveraged data from the Syapse Learning Health Network to generate compelling evidence evaluating the impact of Comprehensive Genomic Profiling on clinical biomarker actionability, therapy selection, and clinical outcomes for advanced NSCLC patients from community oncology practices in the US. CGP tested patients, when compared to patients tested using small panel only, showed the following outcomes: 1. Higher rate of actionability of biomarkers 2. 3x more likely to receive matched approved targeted therapy 3. Reduced risk of mortality. This study solidified that patients who received CGP had improved detection of actionable biomarkers and greater use of matched therapies, both of which were associated with significant increases in survival. These insights contribute to the growing evidence of the power and promise of CGP, and it is critical that this work continues. I am thankful for support and collaboration of our Market Access team championing this research every day! A big Thank You and congratulations to Scott Spencer, PhD Damon Hostin Brock Schroeder, PhD, as well as Jeanna Law Connor Sweetnam Hina Mohammed, MPH Ashleigh McBratney Monika Izano, PhD Molly Scannell Bryan and Anna Berry from Syapse, and George Simon from Moffitt Cancer Center Please read the manuscript here for more.